N6022 is primarily explored for its potential therapeutic applications, particularly in the field of inflammatory and respiratory diseases. It acts as a modulator of S-nitrosoglutathione reductase (GSNOR), an enzyme involved in regulating nitric oxide metabolism. By inhibiting GSNOR, this compound helps maintain higher levels of S-nitrosoglutathione, which can reduce inflammation and improve bronchial function. This mechanism makes it a promising candidate for treating conditions such as asthma, chronic obstructive pulmonary disease (COPD), and other inflammatory disorders. Research is ongoing to further understand its efficacy and safety in clinical settings.